| Effect | Decrease |
| Trial Design | Non-randomized controlled trial |
| Trial Length | 2-4 Weeks |
| Number of Subjects | 10 |
| Sex | Both Genders |
| Age Range | 18-29 |
| Body Types | Average |
In a preliminary study using PQQ at 0.075mg/kg for one week (doubled during week two, and then doubled again to 0.3mg/kg for the final week) in otherwise healthy humans noted a significant reduction in C-reactive protein (45%) and a decrease in IL-6 which paralleled C-RP, but the reduction in lipid peroxidation was very minor (0.2%) and other biomarkers of oxidation were not affected.
Urinary biomarkers suggested that mitochondrial efficiency was influenced in a beneficial manner as urinary fumarate, pyruvic acid, and lactate were all reduced; urinary amino acids were also reduced (suggesting retention of nitrogen) and a decrease in some urinary amines suggested increased beta-oxidation (a measure of fat oxidation).
